Wells Fargo & Company MN Boosts Stock Position in Telomir Pharmaceuticals, Inc. (NASDAQ:TELO)

Wells Fargo & Company MN boosted its holdings in Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) by 458.3% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 10,044 shares of the company’s stock after buying an additional 8,245 shares during the quarter. Wells Fargo & Company MN’s holdings in Telomir Pharmaceuticals were worth $41,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Rhumbline Advisers boosted its stake in Telomir Pharmaceuticals by 105.9% in the fourth quarter. Rhumbline Advisers now owns 8,600 shares of the company’s stock valued at $35,000 after acquiring an additional 4,424 shares in the last quarter. Corebridge Financial Inc. boosted its stake in Telomir Pharmaceuticals by 273.8% in the fourth quarter. Corebridge Financial Inc. now owns 9,613 shares of the company’s stock valued at $40,000 after acquiring an additional 7,041 shares in the last quarter. Barclays PLC boosted its stake in Telomir Pharmaceuticals by 325.1% in the third quarter. Barclays PLC now owns 7,018 shares of the company’s stock valued at $45,000 after acquiring an additional 5,367 shares in the last quarter. Virtu Financial LLC acquired a new position in Telomir Pharmaceuticals in the fourth quarter valued at $62,000. Finally, JPMorgan Chase & Co. boosted its stake in Telomir Pharmaceuticals by 1,096.4% in the fourth quarter. JPMorgan Chase & Co. now owns 41,444 shares of the company’s stock valued at $171,000 after acquiring an additional 37,980 shares in the last quarter.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on the stock. Rodman & Renshaw assumed coverage on shares of Telomir Pharmaceuticals in a research note on Friday, February 21st. They issued a “buy” rating and a $15.00 price objective for the company. RODMAN&RENSHAW upgraded shares of Telomir Pharmaceuticals to a “strong-buy” rating in a research note on Thursday, February 20th.

Telomir Pharmaceuticals Price Performance

NASDAQ TELO opened at $2.66 on Thursday. Telomir Pharmaceuticals, Inc. has a 1 year low of $2.35 and a 1 year high of $8.40. The company has a market capitalization of $79.17 million, a PE ratio of -4.59 and a beta of 0.17. The company has a fifty day moving average of $3.16 and a two-hundred day moving average of $4.04.

Telomir Pharmaceuticals (NASDAQ:TELO) last announced its earnings results on Monday, May 12th. The company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.10) by $0.03. On average, research analysts expect that Telomir Pharmaceuticals, Inc. will post -0.4 earnings per share for the current year.

Telomir Pharmaceuticals Company Profile

Telomir Pharmaceuticals, Inc, a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems.